



Publication of insider information pursuant to Art. 17 MAR

Carl Zeiss Meditec AG achieves strong revenue and EBIT growth in first three months 2018/19

Jena, January 14, 2019

Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of approximately EUR 324 million in the first three months of fiscal year 2018/19, based on preliminary data. This corresponds to revenue growth of around 10% vs. the previous year's value of EUR 294.7 million. Currency effects only had a minor impact on growth.

In the same period, earnings before interest and taxes (EBIT) increased significantly to EUR 48.1 million (prev. year EUR 38.9 million). This corresponds to an EBIT margin (EBIT in percent of revenue) of 14.9% (prev. year 13.2%). EBIT was positively impacted by temporarily reduced research & development expenses. For fiscal year 2018/19, the company still expects an EBIT margin between 14% to 16%.

The 3-months quarterly statement for fiscal year 2018/19 will be published on February 11, 2019.

Contact for investors and press

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on MDAX and TecDax of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery.

With approximately 3,050 employees worldwide, the Group generated revenue of €1,280.9m in fiscal year 2017/18 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med